Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14578756 | 0.88 | ALDH1A1 (0.58) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL7239944 | 0.87 | ALDH1A1 (0.59) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL15833291 | 0.86 | CA2 (0.51) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL12237305 | 0.85 | GAA (0.51) | ALDH1A1KMT2ALMNACA2GAA | |
| SCHEMBL114044 | 0.85 | ALDH1A1 (0.57) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL3298234 | 0.85 | ALDH1A1 (0.55) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL14578750 | 0.85 | LMNA (0.61) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL5711929 | 0.85 | CA2 (0.54) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL8752139 | 0.85 | CA2 (0.54) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL12237322 | 0.84 | CA2 (0.53) | ALDH1A1KMT2ALMNACA2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10731004-B2 | Polyimide precursor composition and use thereof | ETERNAL MATERIALS CO., LTD. (TW) | 2020-08-04 | — | — | US | disclosed |
| US-10696793-B2 | Process for preparing polyimides | ETERNAL MATERIALS CO., LTD. (TW) | 2020-06-30 | — | — | US | disclosed |
| US-10626220-B2 | Precursor for polyimide and use thereof | ETERNAL MATERIALS CO., LTD. (TW) | 2020-04-21 | — | — | US | disclosed |
| US-20200055986-A1 | PROCESS FOR PREPARING POLYIMIDES | ETERNAL MATERIALS CO., LTD. (TW) | 2020-02-20 | — | — | US | disclosed |
| US-20180148544-A1 | PRECURSOR FOR POLYIMIDE AND USE THEREOF | ETERNAL MATERIAL CO., LTD. (TW) | 2018-05-31 | — | — | US | disclosed |
| US-20180148541-A1 | POLYIMIDE PRECURSOR COMPOSITION AND USE THEREOF | ETERNAL MATERIALS CO., LTD. (TW) | 2018-05-31 | — | — | US | disclosed |
| US-20180148541-A1 | POLYIMIDE PRECURSOR COMPOSITION AND USE THEREOF | ETERNAL MATERIALS CO., LTD. (TW) | 2018-05-31 | — | — | US | disclosed |
| US-20180148544-A1 | PRECURSOR FOR POLYIMIDE AND USE THEREOF | ETERNAL MATERIAL CO., LTD. (TW) | 2018-05-31 | — | — | US | disclosed |
| US-20160367091-A9 | Personal Care Compositions Comprising a Di-Amido Gellant and Methods of Using | THE PROCTER & GAMBLE COMPANY | 2016-12-22 | — | — | US | disclosed |
| US-9387254-B2 | Prodrugs and drug-macromolecule conjugates having controlled drug release rates | PROLYNX LLC (US) | 2016-07-12 | — | — | US | disclosed |
| CN-101503394-B | High piperazine acetydrazide derivatives, and preparation and use thereof | SHENZHEN XIANGYA BIOLOGY MEDICAMENT ACADEMY | 2010-05-12 | — | — | CN | disclosed |
| WO-2010034832-A1 | MONOAZO DYES FOR DYEING LEATHER | BASF SE (DE) | 2010-04-01 | — | — | WO | disclosed |
| CN-101503394-A | High piperazine acetydrazide derivatives, and preparation and use thereof | SHENZHEN XIANGYA BIOLOGY MEDIC (CN) | 2009-08-12 | — | — | CN | disclosed |
| US-7550458-B2 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-20070234488-A1 | Method for the Reactive Coloration of Leather | BASF AKTIENGESELLSCHAFT (DE) | 2007-10-11 | — | — | US | disclosed |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
| EP-1556371-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | WINSTON PHARMACEUTICALS LLC (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1556371-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | Winston Pharmaceuticals LLC (US) | 2005-07-27 | — | — | EP | disclosed |
| CN-1523989-A | Macrophage migration inhibitory factor inhibitor and identification method thereof | ������˹ҩƷ��˾ | 2004-08-25 | — | — | CN | disclosed |
| WO-2004009583-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | GARST MICHAEL E (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | VDR, ESRRB, NR5A1 | ALDH1A1 3634/4885CYP3A4 628/4885CYP2C9 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.